Amy P. Abernethy, MD PhD is the Chief Medical Officer/Chief Scientific Officer and SVP Oncology at Flatiron Health, a healthcare technology company focused on accelerating research and dramatically improving treatment for people with cancer. She is a hematologist/oncologist and palliative medicine physician, and an internationally recognized cancer clinical researcher.
With over 400 publications, Dr. Abernethy is an expert in cancer outcomes research, clinical trials, patient reported outcomes, evaluation of healthcare quality, health services research, clinical informatics and patient-centered care. She is an appointee to the National Academy of Medicine’s (formerly the Institute of Medicine) National Cancer Policy Forum, on the Executive Board for the Personalized Medicine Coalition, and Past President of the American Academy of Hospice & Palliative Medicine.
Before joining Flatiron, Dr. Abernethy was Professor of Medicine at Duke University School of Medicine, and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support tracking cancer care, drug development, personalized medicine and scientific discovery. Joining Flatiron was the obvious next step.
Dr. Abernethy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine. She is also on the Board of Directors of athenahealth, Inc.